利妥昔单抗生物类似药CT-P10治疗系统性硬化症的安全性与疗效:意大利多中心研究
该回顾性多中心研究纳入33例系统性硬化症患者,评估利妥昔单抗生物类似药CT-P10的安全性与疗效。治疗6个月后,mRSS、28关节DAS和CRP显著下降,肺功能无显著变化,仅1例出现短暂中性粒细胞减少。提示CT-P10可改善皮肤和关节受累并稳定肺功能。
要点
- CT-P10治疗6个月后mRSS、28关节DAS和CRP显著改善。
- 肺功能指标在全体及ILD亚组中均无显著变化。
- 仅1例RTX-Bs患者出现短暂中性粒细胞减少。
核心结论
- CT-P10可有效改善SSc患者皮肤和关节受累并稳定肺功能,安全性良好。
研究设计与样本
- 回顾性多中心研究,从6个意大利转诊中心识别接受CT-P10且随访至少6个月的SSc患者。
主要发现
- 33例患者中女性29例(87.9%),平均年龄51.6岁(s.d. 14.2),平均病程9.8年(s.d. 8.1)。
- 21例(64.5%)为dcSSc,20例(60.1%)抗拓扑异构酶I阳性,7例(21.2%)抗RNA聚合酶III阳性,6例(18.2%)抗着丝点阳性。
- 治疗6个月后mRSS、28关节DAS和CRP显著下降(P分别为0.002、0.005和0.008)。
- mRSS在RTX-Bn组(P<0.024)和RTX-Bs组(P<0.031)均显著改善。
- 肺功能检查在全体队列及ILD亚组中均无显著变化。
关键数值与推荐
- RTX-B引入原因:皮肤进展18例(54.5%),ILD恶化11例(33.3%),关节炎12例(36.4%)。
临床怎么用
- CT-P10可作为SSc患者更经济的治疗选择,尤其适用于皮肤和关节受累者。
- 对ILD患者,CT-P10可稳定肺功能,但需监测肺功能变化。
局限性
- 回顾性设计,样本量较小(33例),随访仅6个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Recent data have shown a significant efficacy of rituximab (RTX) in SSc. An RTX biosimilar (RTX-B) is a more affordable option. We assessed the safety and efficacy of an RTX-B (CT-P10) in SSc. METHODS: SSc patients treated with RTX-B with at least 6 months of follow-up were retrospectively identified from six Italian referral centres. SSc patients naïve to RTX-B (RTX-Bn) or already treated with RTX originator and switched to an RTX-B (RTX-Bs) were evaluated. A comprehensive assessment of disease characteristics and organ involvement at baseline and after 6 months was obtained. RESULTS: Thirty-three SSc patients were selected: 29 (87.9%) females, mean age 51.6 years (s.d. 14.2), mean disease duration 9.8 years (s.d. 8.1); 21 (64.5%) with dcSSc, 20 (60.1%) anti-topoisomerase I, 7 (21.2%) anti-RNA polymerase III and 6 (18.2%) anti-centromere positive. Seventeen (51.5%) were RTX-Bn and 16 were on RTX-Bs (48.5%). RTX was introduced because of skin progression in 18 patients (54.5%), interstitial lung disease (ILD) worsening in 11 (33.3%) and arthritis in 12 (36.4%). All patients were previously treated with immunosuppressants. At RTX-B introduction, 21 (63.6%) patients were on concomitant immunosuppressants: 15 (71.4%) on MMF and 6 (28.6%) on MTX. Twenty-three (69.7%) were on low-dose steroids. After 6 months, a significant reduction of the modified Rodnan skin score (mRSS), 28-joint DAS and CRP was observed (P = 0.002, 0.005 and 0.008, respectively); the mRSS significantly improved both in RTX-Bn (P < 0.024) and RTX-Bs patients (P < 0.031). No significant changes were observed for lung function tests, either in the entire cohort or in the subgroup of ILD patients. Only one RTX-Bs patient experienced transient neutropenia. CONCLUSION: Our data suggest that RTX-B can represent a cheaper option in SSc patients, as it is effective in improving skin and joint involvement and in stabilizing lung function.
引用
- Campochiaro C, De Luca G, Lazzaroni MG, et al. Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study. Rheumatology (Oxford). 2020. PMID: 32413118. doi:10.1093/rheumatology/keaa136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。